Justification of 150 mg clopidogrel in patients with high on‐clopidogrel platelet reactivity
Authors:
- 9 September 2011
- journal article
- research article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 42 (4) , 384-392
Abstract
Eur J Clin Invest 2012; 42 (4): 384–392 Background The GRAVITAS trial showed that 150 mg clopidogrel did not improve outcome in patients with high on‐clopidogrel platelet reactivity (HPR) screened by the VerifyNow assay. We aimed to determine the impact of 150 mg clopidogrel in stable angina patients with HPR identified with conventional aggregometry (LTA).Materials and methods Clopidogrel‐naive stable angina patients before ad hoc percutaneous coronary intervention were recruited into a randomized, double‐blind, placebo‐controlled trial (NCT00638326). Twelve to 24 h after the 600‐mg loading dose of clopidogrel, ADP5μM‐stimulated maximal (AGGmax), late platelet aggregation (AGGlate) and vasodilator‐stimulated phosphoprotein phosphorylation (VASP‐PRI) were evaluated. Patients with HPR (AGGmax ≥ 34%) were randomly allocated to 75 or 150 mg clopidogrel after 4 weeks. After control platelet function measurements at day 28, 75 mg clopidogrel was administered to all patients until 1 year.Results The study was prematurely terminated at the stage of 200 enroled patients. Administration of 150 mg clopidogrel significantly reduced platelet aggregation (AGGmax: 45·0 ± 6·8 vs. 33·8 ± 15·1, P < 0·01; AGGlate: 27·1 ± 14·7 vs. 13·8 ± 18·0, P < 0·01) and VASP‐PRI (57·5 ± 15·2 vs. 37·2 ± 17·1; P < 0·01), while platelet reactivity remained unchanged in patients with HPR receiving 75 mg clopidogrel. The higher maintenance dose of clopidogrel was associated with a significant reduction in cardiovascular (CV) death and myocardial infarction (MI) (0% vs. 11·4%, P = 0·04) and in CV death, MI or target vessel revascularization (24·6% vs. 3·1%; P = 0·01) during 1 year.Conclusions One‐month administration of 150 mg maintenance dose of clopidogrel reduces platelet reactivity and might decrease the risk of thrombo‐ischaemic complications in stable angina patients with HPR identified by LTA.Keywords
This publication has 26 references indexed in Scilit:
- Prasugrel Overcomes High On-Clopidogrel Platelet Reactivity Post-Stenting More Effectively Than High-Dose (150-mg) ClopidogrelJACC: Cardiovascular Interventions, 2011
- Platelet function monitoring in patients on clopidogrelInterventional Medicine and Applied Science, 2011
- Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary SyndromesNew England Journal of Medicine, 2010
- Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary StentsNew England Journal of Medicine, 2010
- Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivityPlatelets, 2009
- Can We Override Clopidogrel Resistance?Circulation, 2009
- Thienopyridine Therapy Influences Late Outcome After Coronary Stent ImplantationAngiology, 2008
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent PlacementJACC, 2006
- Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stentingAmerican Heart Journal, 2005